{"created":"2023-06-20T15:59:54.768962+00:00","id":18057,"links":{},"metadata":{"_buckets":{"deposit":"0f3d2701-152a-4703-8e18-5ddd81df73a6"},"_deposit":{"created_by":27,"id":"18057","owners":[27],"pid":{"revision_id":0,"type":"depid","value":"18057"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00018057","sets":["99:64:704"]},"author_link":["68702","68701"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-03-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"8","bibliographicPageStart":"1","bibliographicVolumeNumber":"27","bibliographic_titles":[{"bibliographic_title":"徳島赤十字病院医学雑誌"}]}]},"item_10002_heading_23":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著","subitem_heading_language":"ja"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1346-9878","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"近藤, 剛史"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-25"}],"displaytype":"simple","filename":"01_近藤剛史Dr.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"tokushima00329","url":"https://redcross.repo.nii.ac.jp/record/18057/files/01_近藤剛史Dr.pdf"},"version_id":"b2a05f0b-55c2-4e13-a487-2ac74c9a72ef"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"2型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"GLP-1受容体作動薬","subitem_subject_scheme":"Other"},{"subitem_subject":"Dulaglutide","subitem_subject_scheme":"Other"},{"subitem_subject":"SGLT2阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"type 2 diabetes","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glucagon-like peptide-1 receptor agonist","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"sodium-glucose cotransporter-2 inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"強化インスリン療法中の2型糖尿病患者におけるDulaglutide・SGLT2 阻害薬の併用効果","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"強化インスリン療法中の2型糖尿病患者におけるDulaglutide・SGLT2 阻害薬の併用効果"},{"subitem_title":"Add-on effects of dulaglutide and sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus undergoing intensified insulin therapy","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"27","path":["704"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-04-25"},"publish_date":"2022-04-25","publish_status":"0","recid":"18057","relation_version_is_last":true,"title":["強化インスリン療法中の2型糖尿病患者におけるDulaglutide・SGLT2 阻害薬の併用効果"],"weko_creator_id":"27","weko_shared_id":-1},"updated":"2023-06-20T17:47:50.788841+00:00"}